Get the Stockscreener App
1.87
4.10%
-0.08
After Hours:
1.85
-0.02
-1.07%
Compass Therapeutics Inc stock is traded at $1.87, with a volume of 11.48M.
It is down -4.10% in the last 24 hours and down -65.94% over the past month.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
See More
Previous Close:
$1.95
Open:
$1.9
24h Volume:
11.48M
Relative Volume:
1.85
Market Cap:
$336.76M
Revenue:
$850.00K
Net Income/Loss:
$-68.17M
P/E Ratio:
-5.9687
EPS:
-0.3133
Net Cash Flow:
$-49.17M
1W Performance:
+11.98%
1M Performance:
-65.94%
6M Performance:
-53.25%
1Y Performance:
+10.65%
1-Day Range:
$1.84
$1.945
1-Week Range:
$1.67
$2.02
52-Week Range:
$1.61
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
1.87 | 351.17M | 850.00K | -68.17M | -49.17M | -0.3133 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-26 | Initiated | Craig Hallum | Buy |
| Jan-05-26 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Canaccord Genuity | Buy |
| Dec-03-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Compass Therapeutics 4Q Research and Development Expenses $13.4M >CMPX - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
2026-05-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Investors to Learn More About the Investigation | NDAQ:CMPX | Press Release - Stockhouse
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update - Investing News Network
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX) - Yahoo Finance
Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary - TradingView
CMPX: Q1 2026 net loss rose to $18.3M; tovecimig advanced with positive BTC data and FDA orphan status - TradingView
Compass Therapeutics Q1 net loss widens on higher R&D, G&A costs - TradingView
CMPX: Tovecimig achieved key clinical milestones in BTC, with strong cash reserves supporting future trials - TradingView
Press Release: Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Stockholders to Connect - ACCESS Newswire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
LifeSci Capital Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
CMPX Stock Plunges As Traders Weigh Cancer Trial Fallout - StocksToTrade
CMPX Stock Price, Quote & Chart | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc.CMPX - PR Newswire
Compass Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Compass Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Anderman Jonathanmoomoo - Moomoo
Compass Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Lerner Neilmoomoo - Moomoo
Compass Therapeutics | DEFA14A: Others - Moomoo
Compass Therapeutics general counsel Jonathan Anderman buys $47,250 in stock - Investing.com India
Compass Therapeutics chief accounting officer buys $28,350 in stock - Investing.com UK
Compass Therapeutics general counsel Jonathan Anderman buys $47,250 in stock By Investing.com - Investing.com South Africa
Compass Therapeutics chief accounting officer buys $28,350 in stock By Investing.com - Investing.com India
Compass Therapeutics (NASDAQ: CMPX) CAO buys 15,000 shares - Stock Titan
Compass Therapeutics (CMPX) general counsel buys more company stock - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutics, Inc. (CMPX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Compass Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lerner Neil - Moomoo
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass Therapeutics (CMPX) CAO receives 15,000-share equity grant - Stock Titan
CMPX Stock Sinks As Trial Failure Hammers Compass Therapeutics - StocksToTrade
CMPX Stock Plunges As Trial Failure Triggers Downgrade And Probe - StocksToTrade
Compass Therapeutics | DEF 14A: Definitive information statements - Moomoo
[DEF 14A] Compass Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity? - Yahoo Finance
Compass Therapeutics’s stock crashes after OS miss in BTC trial - MSN
[ARS] Compass Therapeutics, Inc. SEC Filing - Stock Titan
Compass Therapeutics (CMPX) Is Down 65.4% After Tovecimig Combo Meets Key BTC Trial EndpointsWhat's Changed - Sahm
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings - Sahm
US Stocks Mixed; Nasdaq Falls Over 100 Points - Sahm
Citizens Jmp Reiterates Market Outperform Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
A Quick Look at Today's Ratings for Compass Therapeutics(CMPX.US), With a Forecast Between $6 to $24 - Moomoo
Raymond James Downgrades Compass Therapeutics to Market Perform From Outperform - marketscreener.com
Raymond James downgrades Compass Therapeutics stock rating on trial results - Investing.com Canada
ABL Bio Partner Compass to Pursue FDA Approval Despite Missed Survival Endpoint - Seoul Economic Daily
CMPX - Finviz
Compass drug shows mixed late-stage results, shares slide - The Pharma Letter
Compass Therapeutics stock rating maintained at outperform by Citizens - Investing.com
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):